reported that involve small patient populations ( 15 -18 ) , and one Web-based survey of 1203 users ( 19 ) has also been reported. Recent press reports ( 20 , 21 ) and a systematic review of data from 368 case patients reported in 10 case series studies ( 1 ) have raised the visibility of this association in the medical community and general public.
The mechanism that underlies the association between in travenous bisphosphonate treatment and jaw osteonecrosis is not understood. Current explanations include an infectious etiology, the loss of blood supply, or the suppression of bone turnover ( 1 , 7 , 22 , 23 ) . There is also a lack of information on the epidemiology of the toxicity. There is no information from prospective trials and only limited information from observational cohorts on incidence, time course, or other risk factors ( 15 -19 ) .
Recent studies have used tumor registry data from the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare claims data to examine toxicities of parenterally administered drugs ( 24 , 25 ) . A challenge in using this approach to investigate toxicity from intravenous bisphosphonates is that there is no specifi c code in the ninth revision of the International Classifi cation of Diseases (ICD-9) for osteonecrosis of the jaw. Therefore, we chose two outcomes with ICD-9 codes that should be closely related to jaw osteonecrosis: 1) a diagnosis of infl ammatory conditions or osteomyelitis of the jaw and 2) an operation on the jaw or facial bones. In this study, we investigated the association between intravenous treatment with pamidronate or zoledronic acid and a subsequent diagnosis of infl ammatory conditions or osteomyelitis of the jaw or an operation on the jaw or facial bones.
Patients and Methods

Data Sources
The SEER -Medicare linked database contains tumor characteristics and demographic information for Medicare beneficiaries newly diagnosed with cancer in geographic regions covered by the SEER program ( 26 ) . In 2002, the program included registries that covered approximately 26% of the US population. Medicare data were linked to these patients' SEER records through a collaborative program between the National Cancer Institute and the Center for Medicare and Medicaid Services. Approximately 94% of the SEER records for beneficiaries aged 65 years and older were matched to the patients' claims for medical services.
Study Subjects
We first selected individuals diagnosed with any cancer during the period from January 1, 1986, through December 31, 2002 . Using the Health Care Procedure Coding System (HCPCS) drug administration codes J2430 for pamidronate and J3487 for zoledronic acid, we then identified subjects (bisphosphonate recipients) among those who had received at least one injection of the bisphosphonate pamidronate disodium (Aredia) or zoledronic acid (Zometa) from January 1, 1995, through December 31, 2003 . Patients who were not enrolled in both Medicare part A and part B for the 12 months before the first bisphosphonate injection, who were members of a health maintenance organization for 12 months before the first injection, or whose cancer was first diagnosed by autopsy or indicated on a death certificate were excluded from this study. Individuals who experienced a study outcome in the 12 months before study entry were also excluded. Overall, data were available for 16 073 bisphosphonate users for dose -response analyses (see Table 3 ).
For analyses comparing site of jaw toxicity associated with bisphosphonate use ( see Fig. 1 and Tables 1 and 2 ) , we matched each bisphosphonate user to two nonusers. Nonusers were selected from among cancer patients who had not received any bisphosphonate therapy from January 1, 1995, through December 31, 2003 . Nonusers who were not enrolled in both Medicare part A and part B for the 12 months before study entry, whose cancer was fi rst diagnosed by autopsy or indicated on a death certifi cate, or who experienced a study outcome in the 12 months before study entry were excluded from the study. Study entry for a nonuser was the month and year of the fi rst bisphosphonate injection received by the user to which the nonuser was matched. We used a twostep sequential matching process. In the fi rst step, patients who had not received bisphosphonates were matched with those who had by type of cancer (breast, lung, prostate, multiple myeloma, or all other cancers), age at bisphosphonate administration (<65, 65 -69, 70 -74, 75 -79, or ≥ 80 years), month and year of the fi rst
CONTEXT AND CAVEATS
Prior knowledge
Associations between osteonecrosis of the jaw or facial bones and treatment with intravenous bisphosphonates have been reported from small studies.
Study design
Population-based cohort study of data from the Surveillance, Epidemiology, and End Results program linked to Medicare claims.
Contribution
In a large study of 14 349 bisphosphonate users and 28 698 nonusers, use of bisphosphonates, compared with its nonuse, was associated with substantially increased risks of jaw or facial surgery or of being diagnosed with inflammatory conditions or osteomyelitis of the jaw.
Implications
Increased risks of jaw complications among bisphosphonate users may reflect an increased risk for osteonecrosis of the jaw. Increasing oral hygiene and avoiding tooth extractions may lead to a decrease in the incidence of jaw complications. Given the increasing use of intravenous bisphosphonate therapy for treating osteoporosis, these patients should be followed carefully for adverse bone events involving facial bones.
Limitations
Because there is no disease code for facial or jaw osteonecrosis or aseptic necrosis of the jaw, the authors used surrogates, which could introduce some misclassification. Reliance on Medicare claims data required that patients and physicians be aware of their condition or that patients had undergone treatment by a clinician who billed Medicare; underreporting could have occurred if patients had unreported disease or were treated by a dentist who could not charge Medicare. ( 27 ) . In addition, a comorbidity score was calculated by use of Klabunde's adaptation of the Charlson comorbidity index in the SAS macro provided by the National Cancer Institute ( 28 ) . For both the risk factor index and comorbidity score, we searched the inpatient, outpatient, and physician files for any of those diagnoses in the 12 months before study entry, as previously described ( 27 , 28 ) . To avoid double counting the effect of diabetes, we removed diabetes from the Klabunde comorbidity score above. Receipt of parenteral corticosteroids and diagnosis of bone metastasis in the 12 months before to the 1 month after date of study entry (for bisphosphonate users, month and year of first bisphosphonate injection; for nonusers, month and year of first bisphosphonate injection of the user to which a nonuser is matched) were assessed with HCPCS codes J1094, J1100, J1700, J1710, J1720, and J2650 and with ICD-9 code 198.5.
Outcomes
The study outcomes were diagnoses of inflammatory conditions or osteomyelitis of the jaw (ICD-9 526.4) and operations on the fa cial bones and joints (ICD-9 procedure codes 76. ( 28 ) . In preliminary analyses, we also assessed the utility of ICD-9 code 773.40 (aseptic necrosis -site unspecified). However, that diagnosis appeared to be used for aseptic necrosis at sites other than the jaw and facial bones. For example, more than 60% of patients with the code 733.40 also had a site-specific code for aseptic necrosis (e.g., aseptic necrosis of the hip or the shoulder). Therefore, we did not include 733.40 as an outcome in our analyses. However, in the analyses that did include it, the direction and statistical significance of the results were unaltered.
Dose Estimation
Medicare claims forms document the number of units administered in each bisphosphonate injection. We estimated cumulative dose by calculating the number of units recorded during the period of follow-up for each bisphosphonate user. Because the units for pamidronate and zoledronic acid differ, we used 4 mg of zoledronic acid and 90 mg of pamidronate as equivalent doses. Both the number of units and the equivalent dose were analyzed as continuous and as categorical variables (number of injections: ≤ 3, 4 -8, 9 -13, 14 -21, or >21). We considered the number of injections to be an indicator of dose and compared the number of injections with the number of units and dose-equivalent measures.
Statistical Analysis
Unadjusted event-free survival was estimated by the Kaplan -Meier method ( 29 ) . Multivariable survival analyses (see Tables 2 and 3 ) were performed by use of Cox proportional hazards regression with the dependent variable being time to first occurrence of a study outcome (i.e., inflammatory conditions or osteomyelitis of the jaw or surgery on the jaw or facial bones). We tested the assumption of proportionality in the Cox model by determining that the logarithm of the baseline cumulative hazard rates and the Schoenfeld residuals were proportional with follow-up time ( 29 , 30 ) . Patients were censored at death, at loss of Medicare part A and part B coverage, or at the end of the study (i.e., December 31, 2003) . Patient and cancer characteristics and treatment with intravenous bisphosphonate therapy were treated as independent variables.
We assessed the dose -response relationship among intravenous bisphosphonate recipients in two ways. First, cumulative dose over time was modeled in Cox proportional hazard models as a time-dependent covariate among all study patients who received bisphosphonate therapy (n = 16 073). Second, after restricting eligibility to recipients with more than 12 months of follow-up time (n = 6343), we estimated the hazard ratio (HR) for any study outcome by cumulative dose category for injections received during the fi rst 12 months. All analyses were performed with the SAS package of computer programs version 9.1 (SAS Institute, Cary, NC). We did not estimate power before beginning the study. All statistical tests were two-sided.
Results
Characteristics of all intravenous bisphosphonate users and of the matched intravenous bisphosphonate users and nonusers are presented in Table 1 . Among all intravenous bisphosphonate users, 82.3% were diagnosed with cancer of the lung, breast, or prostate or with multiple myeloma. The use of intravenous bisphosphonates to treat patients in the study increased from 170 patients in 1995 to 5348 patients in 2003. Although zoledronic acid was introduced in 2001, a separate drug administration code for it did not We investigated event-free survival among the matched intravenous bisphosphonate users and nonusers by use of Kaplan -Meier curves. Results for three outcomes are shown in Fig. 1 : surgery on facial bones or jaw, diagnosis of infl ammatory conditions or osteomyelitis of the jaw, and either of these outcomes. As noted above, we used a diagnosis of infl ammatory conditions or osteomyelitis of the jaw or operations on the jaw and facial bones as potential indicators for jaw osteonecrosis because there is no specifi c ICD-9 code for the diagnosis of jaw osteonecrosis. By 18 months, the survival curves for the bisphosphonate users differed statistically signifi cantly from those of the nonusers for each outcome ( P <.001) by log-rank test. The curves for users and nonusers continued to diverge over time. At 6 years, 5.48% (95% confi dence interval [CI] = 3.63% to 7.33%) of users had been diagnosed with infl ammatory conditions or osteomyelitis of the jaw or underwent jaw or facial surgery, compared with 0.30% (95% CI = 0.19% to 0.42%) of nonusers, resulting in an absolute risk of 5.48 events per 100 bisphosphonate users and an absolute risk of 0.30 events per 100 nonusers at 6 years.
We next investigated whether the association between intravenous bisphosphonate therapy and jaw toxicity was independent of other factors that might contribute to jaw toxicity ( Table 2 ). The risk index is composed of specifi c comorbidities associated with increased risk of aseptic necrosis, including diabetes, alcoholism, cigarette smoking, obesity, hyperlipemia, pancreatitis, and chemotherapy with l -asparaginese ( 27 ) . After adjustment for these potential confounders, intravenous bisphosphonate use, compared with nonuse, was strongly associated with an elevated risk of a diagnosis of infl ammatory conditions or osteomyelitis of the jaw (HR = 11.48, 95% CI = 6.49 to 20.33), operations on the facial bones (HR = 3.15, 95% CI = 1.86 to 5.32), or either outcome (HR = 4.94, 95% CI = 3.33 to 7.34) ( Table 2 ) .
We also conducted multivariable analyses in which we examined dose -response relationships among all bisphosphonate users ( Table 3 ) . Increases in the risk of infl ammatory conditions or osteomyelitis of the jaw were observed with increases in the cumulative intravenous bisphosphonate dose (for 4 -8 dose-equivalent units of intravenous bisphosphonate compared with 3 units or fewer, adjusted HR = 1.56, 95% CI = 0.67 to 3.60; for at least 21 units, HR = 3.57, 95% CI = 1.46 to 8.75). Similar patterns were observed for the risk of operations on the jaw and facial bones (for 4 -8 dose-equivalent units compared with 3 units or fewer, HR = 3.63, 95% CI = 0.77 to 17.08; for at least 21 units, HR = 9.18, 95% CI = 1.74 to 48.53) and for either operations on the jaw or facial bones or infl ammatory conditions or osteomyelitis of the jaw (for 4 -8 dose-equivalent units compared with 3 units or fewer, HR = 1.61, 95% CI = 0.76 to 3.44; for at least 21 units, HR = 3.67, 95% CI = 1.58 to 8.51). For all three outcomes investigated, hazard ratios increase as cumulative dose increases. Other factors associated with any adverse outcome were year of drug administration, SEER registry geographic region, and a diagnosis of multiple myeloma.
The dose -response analyses in Table 3 used the cumulative bisphosphonate dose for the entire study period as a time-dependent covariate. In a separate analysis, we assessed the total bisphosphonate dose received for the 12 months after the fi rst dose and assessed jaw toxicity starting at 12 months ( Table 4 ) . These analyses were restricted to the 6343 patients with more than 12 months of follow-up after receipt of a bisphosphonate. Each one-dose increase in bisphosphonates received in the fi rst 12 months was associated with an 8% increase in the risk of any adverse jaw outcome (HR = 1.08, 95% CI = 1.02 to 1.14).
In the multivariable models shown in Tables 2 and 3 , we also tested for interactions between bisphosphonate use and all other * HR = hazard ratio; CI = confidence interval. † Equivalent doses (considered as one dose) were 90 mg for pamidronate and 4 mg for zoledronic acid. ‡ None of the lung cancer patients had surgery on the jaw or facial bones; therefore, the hazard ratio could not be estimated. NA = not available. § Diabetes was removed from Charlson index (28) .
|| Summary index of risk factors for osteonecrosis includes diabetes, alcoholism, cigarette smoking, obesity, hyperlipidemia, pancreatitis, and chemotherapy with L -asparaginase. covariates (such as age, type of cancer, or sex of patient). There were no statistically signifi cant interactions. Thus, the association of bisphosphonate use with jaw toxicity did not vary by age, sex, type of cancer, or other characteristics analyzed.
Discussion
We found that use of intravenously administered nitrogen-containing bisphosphonates, compared with nonuse, was associated, in a dose -response manner, with an increase in Medicare claims related to jaw and facial bone disease. This study is, to our knowledge, the first of a large, representative population-based cohort of bisphosphonate users and matched nonusers, and our results are consistent with those of several previous studies ( 15 , 16 , 19 ) . In a study of 252 patients using bisphosphonates, Bamias et al. ( 15 ) reported cumulative hazards of 3% (95% CI = 1% to 5%), 7% (95% CI = 1% to 13%), and 11% (95% CI = 3% to 19%) for osteonecrosis of the jaw at 24, 36, and 48 months after first use, respectively. Dimopoulos et al. ( 16 ) reported that, for a 10-year period, 15 patients (7.4%) of the 202 multiple myeloma patients studied who received intravenous bisphosphonates were diagnosed with osteonecrosis of the jaw. In this study, we found not only a strong association between intravenous bisphosphonate therapy and jaw and facial bone disease but also a pattern in which risk estimates for this disease increased as the cumulative dose of intravenous bisphosphonate increased. This fi nding is consistent with the observation that bisphosphonates have a long half-life and remain in the bone for an extensive period of time ( 15 ) . It has been speculated that oversuppression of bone turnover may be related to the length and amount of exposure and the long half-life that characterize bisphosphonates ( 1 , 15 ) .
Several previous studies have found that osteonecrosis of the jaw is more likely to occur among patients treated with zoledronic acid than with other bisphosphonate formulations. The largest of these studies, a study of 1203 patients who had received either pamidronate or zoledronic acid and who responded to an online survey ( 19 ) , reported that 10% of the patients using zoledronic acid and 4% of those using pamidronate developed osteonecrosis of the jaw or had suspicious symptoms after 36 months of follow-up. In a study of 303 multiple myeloma patients, Zervas et al. ( 17 ) reported that a higher risk for osteonecrosis of the jaw was associated with use of zoledronic acid than use of pamidronate (relative risk = 9.5, 95% CI = 1.0 to 83.2). Bamias et al. ( 15 ) found that all cases of jaw osteonecrosis occurred among patients treated with zoledronic acid (n = 17), either alone (n = 7) or in combination with pamidronate (n = 9) or ibandronate (n = 1). They also reported that the cumulative risk associated with duration of treatment increased from 1% after 1 year to 21% after 3 years of treatment with zoledronic acid compared with a cumulative risk of 0% after 2 years to 7% after 4 years of treatment with pamidronate alone or in combination with zoledronic acid ( 19 ) . Thus, the risk of osteonecrosis of the jaw appears to be more strongly associated with zoledronic acid use than with pamidronate use. We were unable to address the issue of relative toxicity of zoledronic acid versus pamidronate in our analyses because, although zoledronic acid was introduced in 2001, there was a delay in issuing a separate billing code for zoledronic acid until 2002.
No clear associations were found by us between adverse outcomes and sex, ethnicity, type of cancer, comorbidity, or with known risk factors for jaw and facial bone disease, including diabetes, alcoholism, cigarette smoking, obesity, hyperlipidemia, pancreatitis, chemotherapy with l -asparaginase, or receipt of parenteral corticosteroids ( 27 ) . That is, the risks for infl ammatory disease or osteomyelitis of the jaw and for jaw surgery after exposure to intravenously administered bisphosphonate were not affected by the presence of other risk factors.
This study has several limitations. First, because there is no ICD-9 code for facial or jaw osteonecrosis or aseptic necrosis of the jaw, we relied on indirect measures, including operations on the jaw or facial bones or a diagnosis of infl ammatory conditions or osteomyelitis of the jaw ( 31 ). Some misclassifi cation was likely * HR = hazard ratio; CI = confidence interval; IV = intravenous; NA = not available. † Doses were 90 mg for pamidronate and 4 mg for zoledronic acid. ‡ None of the lung cancer patients had jaw surgery; therefore, the hazard ratio could not be calculated. present because it was not possible to separate patients with osteonecrosis from those with the other conditions in these categories. Second, our reliance on Medicare claims required that patients and physicians be aware of their condition or had undergone treatment by a clinician who billed Medicare. Many patients may have had unreported disease that would only be recognized by screening patients who were receiving or had received bisphosphonate therapy ( 32 ) , and many patients may have been treated by dentists, rather than by an oral surgeon, without a Medicare charge being generated. If such underreporting existed, however, it would have caused us to underestimate the number of osteonecrosis cases among both bisphosphonate users and nonusers, which would have caused us to underestimate the absolute risk of jaw complications associated with use of intravenous bisphosphonates. Third, Medicare claims data provide no information on oral bisphosphonate use. In several case series of jaw osteonecrosis, fewer than 10% of such patients had received oral bisphosphonates ( 1 , 6 -12 ) . A recent case -control study using health insurance claims data ( 32 ) reported a nonstatis tically signifi cant 15% increase in jaw procedures associated with oral bisphosphonate use. Fourth, as noted above, we are unable to assess the relative toxicities of pamidronate versus zoledronic acid because of the delay in introduction of a specifi c Medicare billing code for zoledronic acid. In 2006, another nitrogen-containing bisphosphonate, ibandronate, was approved by the Food and Drug Administration for intravenous administration to treat osteoporosis ( 33 ), but our study contains no information on use of that agent. Also, as previously mentioned, there were too few cases in the SEER -Medicare data to allow a comparison between pamidronate and zoledronic acid on jaw toxicity. Fifth, a limitation common to all observational studies is that an association does not prove a causal link. Others ( 12 -14 ) have suggested, for example, that the underlying cancer might be responsible for the osteonecrosis and also that patients using intravenous bisphosphonates are likely to have used other therapies, such as corticosteroids, that might be responsible for the toxicity. Our fi ndings, however, would argue against all of these limitations. First, the presence of bone metastases is not strongly as sociated with the outcomes in our study. Among bisphosphonate users, the risk of osteomyelitis or jaw surgery was similar in cancer patients with bone metastases and in those without metastases ( Table 3 ) . Second, in multivariable analyses ( Tables 2 , 3 , and 4 ), none of the risk factors, such as multiple comorbidities or use of parenteral corticosteroids, had much impact on the relationship between intravenous bisphosphonate use and adverse bone outcome. Third, the dose -response relationship between intravenous bisphosphonate use and jaw disease supports the possibility of a causal association.
Even if the association is ultimately shown to be causal, the toxicity of any therapy must be balanced against its effi cacy. Intravenous bisphosphonate treatment is associated with a substantial benefi t in the form of decreased bone loss and fractures experienced by cancer patients who have bone metastases ( 34 ) . For example, in clinical trials, intravenous pamidronate was statistically signifi cantly associated with a 19% absolute reduction in skeletal events ( P <.001) (i.e., pathologic fracture or need for radiation or surgery) in patients with metastatic breast cancer involving bone and a 17% absolute reduction of skeletal events ( P <.001) in patients with multiple myeloma ( 35 ) . Moreover, increasing attention is being given to promoting oral hygiene and avoiding tooth extractions in patients who have received intravenous bisphosphonates ( 2 , 3 , 7 , 23 ) . Such attention may lead to a decrease in incidence of jaw complications.
Future research should include large clinical trials of intravenous bisphosphonate users who are followed long enough for the development of adverse events such as osteonecrosis of the jaw. Given the increasing use of intravenous bisphosphonate therapy for patients with severe osteoporosis, it is important that patients receiving therapy with both established and new formulations of intravenous bisphosphonates be followed carefully for adverse bone events involving the facial bones that may be indicative of osteonecrosis of the jaw. Large population-based observational studies that rely on Medicare and commercial health insurance claims would also be informative, as would studies of data contained in electronic medical records databases, such as the General Practice Research Database in Great Britain.
